Imugene enters final stages of cancer tumour trials
Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for...
top of page
Search
Helen Barling
Oct 26, 2023
Imugene kicks off world-first cancer drug trial
In a world first, ASX-listed medtech Imugene has dosed the first cancer patient with its novel onCARlytics CD19 virus technology which it...
Helen Barling
Oct 24, 2023
Imugene trials take centre stage at global cancer congress
Imugene is poised to secure further development opportunities for its “super-charged” cell immunotherapy programs after putting them on...
Doug Bright
Sep 28, 2023
FDA clears licence pathway for Imugene cancer trials
The United States Food and Drug Administration has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer...
Michael Philipps
Sep 25, 2023
Imugene stacks up $53.2m for cancer-fighting mission
Cancer fighter Imugene has positioned itself as one of the most cashed-up med-tech companies on the ASX after raising a further $18.2...
Doug Bright
Sep 12, 2023
Imugene secures Japan patent for lung cancer vaccine
Clinical-stage immuno-oncology company Imugene has secured new Japan Patent Office protection for its “PD1-Vaxx” that is currently in the...
Doug Bright
Sep 11, 2023
FDA throws support behind Imugene cancer drug trial
Cancer-fighter Imugene says it has received positive feedback from the United States Food and Drug Administration on its proposed trials...
Doug Bright
Sep 4, 2023
Imugene cleared for next step with anti-cancer virus
Clinical stage cancer-fighting company Imugene has revealed that the phase-one trial of its anti-cancer virus “Vaxinia”, which is...
Matt Birney
Aug 21, 2023
ASX: IMU - Imugene
A worldwide license to attack blood cancer
Michael Philipps
Aug 21, 2023
Imugene cashing up for cancer-crushing mission
Fresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is on a steadfast mission to activate...
Matt Birney
May 25, 2023
ASX: IMU - Imugene
Cancer drug trial green lit by US FDA
bottom of page